Drs Ursula A. Matulonis and Eloise Chapman-Davis discuss overcoming health disparities in endometrial cancer and increasing clinical trial enrollment of Black women.

The US Food and Drug Administration (FDA) has granted breakthrough device designation for Acrivon Therapeutics’ ACR-368 ...

It is well recognized that, in many cases, endometrial carcinoma is a well differentiated tumor bearing ... Supported in part by a National Cancer Institute research grant (C 2421).

The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, ...

In a randomized clinical trial, researchers from Huntsman Cancer Institute at the University of Utah (the U) have found that ...

Researchers have found that fewer sessions of higher dose vaginal cuff brachytherapy work just as well as more frequent, lower-dose treatments for endometrial cancer patients.

Uterine cancer is the fourth most common cancer among women and the most common cancer of a woman's reproductive system. There are two major types of uterine cancer: Adenocarcinoma of the endometrium: ...

High-throughput functional screening is carried out in semi-automated cell-based functional assays to identify product leads with differentiated ... and endometrial cancer. MCLA-117 is a T cell ...